Please login to the form below

Not currently logged in
Email:
Password:

SkyePharma looks at options after bid approach

Shares in UK drug delivery firm rise by 7 per cent after possible sale is mooted

UK drug delivery specialist SkyePharma has announced a strategic review of its business after receiving an unsolicited takeover approach from an unnamed source.

The firm, which develops its own products as well as helping manufacturers make more effective formulations of their existing products, said it had hired US investment bank Lehman Brothers as sole financial advisor to examine its strategic options, including a possible sale.

ìThere is no certainty that the review will result in any change to the present ownership structure of the company,î SkyePharma said in a statement.

SkyePharma has several licensing deals with other drug makers, including GlaxoSmithKline (GSK) for its antidepressant Paxil CR. Analysts believe this string of partnerships will deter larger pharma companies from bidding due to the conflicts of interest with existing operations that might arise.

Analyst Jeremy Batstone at stockbroker Charles Stanley said SkyePharma's ìbroad range of small productsî made it less attractive to a larger company..

ìA private equity firm could extract more value by keeping some parts of the business and selling off other parts,î he said.

In a research note, analysts at Numis said the unnamed bidder was most likely private equity as ìthe company wouldn't fit easily into a larger companyî.

Other potential bidders could be US drug delivery rival Alkermes and two of SkyePharma's existing partners: Endo Pharmaceutical of the US and privately owned Zeneus Pharma.

Shares in Skyepharma hit a 10-year low last month after the firm announced a deeply discounted rights issue to fund crucial late-stage clinical trials of its biggest pipeline hope, the asthma inhaler Flutiform.

The drug could generate annual sales of more than $1bn (?575m) and would rival GSK's Seretide and AstraZeneca's Symbicort if approved.

SkyePharma is the third European drugs business in a month to indicate that it may be sold. Last week Europe's biggest biotech firm Serono said it had hired Goldman Sachs to seek alternatives while German firm Altana said it had also hired the bank to examine options for its pharmaceutical unit.

Last week SkyePharma confirmed that HBM BioVentures, a fund chaired the former chief financial officer of Roche, Henri Meier, had increased its stake in the firm to 6.63 per cent from 5.17 per cent.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics